Founded in 2003 in Paris, France, Nanobiotix (NASDAQ: NBTX) is a pioneering, clinical-stage nanomedicine company developing new approaches to significantly enhance the efficacy of radiotherapy for millions of cancer patients worldwide. The company aims to transform traditional radiotherapy benefits into a cutting-edge treatment for cancer by reshaping tumor cells to enhance the efficacy of radiotherapy, to fight cancer more effectively and efficiently.
The company's innovative technique is based on a physical mode of action that could be widely applicable across numerous cancer types. Nanobiotix's flagship product, NBTXR3, is designed to be directly injected into solid tumors, where it works by increasing the dose and efficacy of radiation used in cancer treatment without increasing the intensity of the radiation therapy. This property is a significant advantage, enabling the product to theoretically treat numerous solid tumor types, irrespective of the patients' genetic profiles.
Apart from its primary focus on oncology, Nanobiotix has also branched into other therapeutic areas with significant unmet medical needs, including Immuno-oncology, neurodegenerative diseases, and cardiovascular diseases. For instance, it is developing NBTX-IV, administered intravenously to demonstrate the possibility of using NBTXR3 nanoparticles systemically.
Nanobiotix has an affiliate company called Curadigm based in France, which is dedicated to bringing nanomedicine to a broader group of patients. Curadigm mainly provides targeted delivery of healthcare to improve patient outcomes.
The company works in collaboration with various highly esteemed institutions worldwide, including Massachusetts General Hospital, Princess Margaret Cancer Center, the University of Texas MD Anderson Cancer Center, and many others. These partnerships play a pivotal role in accelerating Nanobiotix's global development and expanding its impact in the medical field globally.
Nanobiotix’s innovative and forward-thinking approach to cancer treatment earned the company recognition in the pharmaceutical and medical research industry. The company maintains a strong commitment to scientific excellence and adheres to the highest ethical and professional standards in its work.
In 2021, the company began trading on the American NASDAQ, a significant leap in its recognition and financial health, signaling its growing global presence.
In conclusion, Nanobiotix's mission to bring efficient and broadly applicable solutions to unmet medical needs, primarily in cancer care, positions it as a vanguard in the nano-oncology field. With its forward-thinking, patient-focused approach, the company continues to pioneer innovative breakthroughs that could reshape the future of medicine and cancer treatment worldwide.